资料显示，江苏吉贝尔药业股份有限公司位于江苏省镇江市高新技术产业开发园区，成立日期2001年11 月13日，上市日期2020年5月18日，公司主营业务涉及专业从事药品研发、生产、销售。主营业务收入 构成为：利可君片72.72%，尼群洛尔片14.20%，玉屏风胶囊4.88%，其他4.53%，醋氯芬酸肠溶片 3.67%。 吉贝尔所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：融资融券、小盘、创新 药、眼科概念、生物医药等。 分红方面，吉贝尔A股上市后累计派现4.76亿元。近三年，累计派现2.52亿元。 1月15日，吉贝尔盘中下跌2.00%，截至10:48，报29.40元/股，成交3994.42万元，换手率0.67%，总市值 58.63亿元。 截至1月9日，吉贝尔股东户数7406.00，较上期增加3.35%；人均流通股26928股，较上期减少3.24%。 2025年1月-9月，吉贝尔实现营业收入7.04亿元，同比增长9.52%；归母净利润1.97亿元，同比增长 12.80%。 资金流向方面，主力资金净流出207.11万元，特大单买入0.00元，占比0.00%，卖出144.01万元，占比 3.61%； ...

证券日报网讯1月13日，吉贝尔在互动平台回答投资者提问时表示，截至2026年1月9日收市，公司股东 总数为7406户。公司股东情况敬请关注公司披露的定期报告。 ...

Core Viewpoint - Shanghai Gaochong Technology Development Co., Ltd. has been established with a registered capital of 10 million RMB, fully owned by Jiangsu Jibeier Pharmaceutical Co., Ltd. [1] Group 1: Company Information - The legal representative of Shanghai Gaochong Technology Development Co., Ltd. is Liu Binghai [1] - The company is classified as a limited liability company with a business scope that includes technology services, development, consulting, and sales of specialized chemical products [1] - The registered address of the company is located at 668 Shangda Road, Building 1, 5th Floor, Area B, Baoshan District, Shanghai [1] Group 2: Shareholding Structure - Jiangsu Jibeier Pharmaceutical Co., Ltd. holds 100% of the shares in Shanghai Gaochong Technology Development Co., Ltd. [1] Group 3: Business Operations - The business operations include medical research and experimental development, marketing planning, conference and exhibition services, ticketing agency services, business secretary services, and technology intermediary services [1] - The company is authorized to conduct business activities independently based on its business license, except for projects that require approval by law [1] Group 4: Registration and Duration - The business registration is valid until January 8, 2026, with no fixed term thereafter [1] - The registration authority is the Baoshan District Market Supervision Administration [1]

吉贝尔（688566.SH）1月8日在投资者互动平台表示，目前，抗抑郁新药JJH201501生产批件申报工作 正在筹备、开展中，公司将按照有关要求加快推进上述申报工作，有关具体进展情况，敬请关注公司后 续披露的相关信息。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问抑郁症药还需多久申报生产评审？ ...

证券日报网讯1月6日，吉贝尔在互动平台回答投资者提问时表示，报告期末的股东人数属于定期报告应 当披露的信息，为保证信息披露的公平性，公司将在2025年年度报告中披露上述信息。 ...

Group 1 - The core point of the news is that Jibeier Pharmaceutical Co., Ltd. experienced a stock decline of 1.01%, with a current share price of 29.27 yuan and a total market capitalization of 5.837 billion yuan [1] - Jibeier's main business involves drug research, production, and sales, with the revenue composition being: Likujun tablets 72.72%, Niquinlor tablets 14.20%, Yupingfeng capsules 4.88%, others 4.53%, and Acetylsalicylic acid enteric-coated tablets 3.67% [1] Group 2 - Among Jibeier's top ten circulating shareholders, one fund from GF Fund Management, the GF Healthcare Stock A (004851), entered the top ten in the third quarter, holding 959,000 shares, which is 0.48% of the circulating shares [2] - The GF Healthcare Stock A fund has a total size of 5.185 billion yuan, with a year-to-date return of 10.16%, ranking 3520 out of 4195 in its category [2] - The fund manager, Wu Xingwu, has a tenure of 10 years and 325 days, with the fund's total asset size at 10.641 billion yuan and a best return of 85.08% during his tenure [3]

Core Viewpoint - The company has completed the initial public offering (IPO) fundraising project related to the construction of a new research and development center and plans to permanently supplement its working capital with the surplus funds of 28.4987 million yuan [1][3]. Fundraising Basic Situation - The company raised a total of 1,107.161626 billion yuan from the IPO, with a net amount of 1,020.88846119 billion yuan after deducting issuance costs of 86.27316481 million yuan [1][2]. Surplus Fund Situation - The surplus amount of 28.4987 million yuan includes bank interest and cash management income, which will be used to support the company's daily operations and business development needs [3][4]. Project Implementation Progress Adjustment - The company has adjusted the implementation timeline for certain fundraising projects, including the production base construction and the development of new drugs, extending deadlines to ensure compliance with quality management standards [6][7]. Measures for Project Implementation - The company will strictly adhere to relevant regulations and optimize resource allocation to ensure the effective implementation of the fundraising projects [8][9]. Review Procedures and Sponsor Opinions - The board of directors has approved the project adjustments and the use of surplus funds, confirming that the decisions comply with regulatory requirements and do not harm shareholder interests [10][11].

国金证券股份有限公司 关于江苏吉贝尔药业股份有限公司 首发募投项目调整实施进度的核查意见 国金证券股份有限公司（以下简称"国金证券"、"保荐机构"）作为江苏 吉贝尔药业股份有限公司（以下简称"吉贝尔"、"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对吉贝尔 部分首发募投项目结项并将节余募集资金永久补流、部分首发募投项目调整实施 进度事项进行了审慎核查，并发表核查意见如下： | 发行名称 | 2020 | 年首次公开发行股份 | | | --- | --- | --- | --- | | 募集资金总额 | | 110,716.16 | 万元 | | 募集资金净额 | | 102,088.85 | 万元 | | 募集资金到账时间 | 2020 | 年 月 5 | 日 12 | 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）2020 年 4 月 7 日 作出的《关于同意江苏吉贝尔药业股份有限公司首次公 ...

江苏吉贝尔药业股份有限公司 关于部分首发募投项目结项并将节余募集资金永久 补流、部分首发募投项目调整实施进度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688566 证券简称：吉贝尔 公告编号：2025-051 本次结项的首次公开发行股票募集资金投资项目（简称"首发募投项 目"或"募投项目"）名称：研发中心（新址）建设项目 本次节余金额为 2,849.87 万元，下一步使用安排是永久补充流动资金 结合目前首发募投项目"利可君片、尼群洛尔片、玉屏风胶囊、盐酸 洛美沙星滴眼液、益肝灵胶囊等生产基地（新址）建设项目"、"国家一类抗 抑郁新药（JJH201501）、国家一类抗肿瘤新药（JJH201601）研发与试验项 目"的实施情况，拟对项目实施进度进行调整 一、募集资金基本情况 | 发行名称 | 2020 | 年首次公开发行股份 | | | | | --- | --- | --- | --- | --- | --- | | 募集资金总额 | | 万元 110,716.16 | | | | | ...

南财智讯12月29日电，吉贝尔公告，公司于2025年12月29日召开第四届董事会第十九次会议，审议通过 关于部分首发募投项目结项并将节余募集资金永久补流、部分首发募投项目调整实施进度的议案。本次 结项项目为"研发中心（新址）建设项目"，已达到预定可使用状态。该项目节余募集资金金额为 2849.87万元（含银行利息、现金管理收益等收入，未经审计，实际金额以资金转出当日专户情况为 准），拟永久补充流动资金。募集资金全部转出后，公司将注销相应募集资金专户。 ...